Transaction · 0000905148-26-004065

Levin Michaela

Levin Michaela, CBO, reported a transaction classified as grant at Acrivon Therapeutics, Inc. involving 130000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 130000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACBO
ACRVAcrivon Therapeutics, Inc.
Trade date
Aug 31, 2026
Filing date
Sep 02, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded130k$0.00 per share
Holdings after130kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ACRV price since this filing

Daily closing prices, with the filing date and available return windows
ACRV · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -30.2%1w ago +2.3%1d ago -4.2%
Returns since7d -7.4%30d -7.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0000905148-26-004065
Stock Option (Right to Buy)
Transaction date
Aug 31, 2026
Filed Sep 02, 2026, 08:30 PM · 2d delay
Shares
130,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
130,000 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Business Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on September 1, 2027, su…

  2. F2

    Twenty-five percent (25%) of the shares subject to the option vest on September 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter,…

Original filing · 0000905148-26-004065
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ACRV